alexa Pharmacogenetic of Clopidogrel and Platelet Function Testing: The Clinical Impact | Open Access Journals
ISSN: 2155-9864
Journal of Blood Disorders & Transfusion
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Pharmacogenetic of Clopidogrel and Platelet Function Testing: The Clinical Impact

Ahmad Almeman1* and Hassan Khalaf2

1School of Medicine, Qassim University,Almulaida, Buraidah, Al Qassim, Saudi Arabia

2Cardiology Interventional Group, Prince Sultan Cardiac Center (PSCC), Buraidah, Al Qassim, Saudi Arabia

*Corresponding Author:
Ahmad Almeman
School of Medicine
Qassim University
Almulaida, Buraidah
Al Qassim, Saudi Arabia
Tel: 0548889712
E-mail: [email protected]

Received date: December 15, 2015; Accepted date: January 13, 2016; Published date: January 18, 2016

Citation: Almeman A, Khalaf H (2016) Pharmacogenetic of Clopidogrel and Platelet Function Testing: The Clinical Impact. J Blood Disord Transfus 7:334. doi:10.4172/2155-9864.1000334

Copyright: © 2016 Almeman A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Blood Disorders & Transfusion

Cytochrome 450 (CYP 450) 2C19 is a well known polymorphic metabolising enzyme which is responsible for converting clopidogrel to its active form [1]. Measuring the resulting activity based on Platelet Reactivity Units (PRU) or inhibition rates of the platelet is well correlated with the genetic polymorphism in several studies worldwide [1-3]. However, the debate is whether the polymorphism or PRU may result in any significant clinical endpoint.

Generally there are two main confounders, the expected time of the clinical endpoints, and the time of measuring the PRU/inhibition rate following clopidogrel initiation. For the first issue, most of the studies measured the clinical endpoints within 1-24 months, and hence long term endpoints can't be conclusive [4-6]. For the other issue, clopidogrel PRU is difficult to be assumed stable especially for the first month following initiation [7]. Thus, if the study measured it after 5 days and considered long term clinical endpoints, it is unlikely to spot a real effect, if exist [8-12]. Accordingly, it is difficult to predict the clinical response for individual patients in short-term studies and just after clopidogrel initiation.

We presented two different studies: in-patient and out-patient cohorts, both showed clear polymorphic population, but no clinical associations were seen in both [7,13,14]. The PRUs were significantly different in our out-patient cohort compared to the in-patient cohort. This is likely due to the unstable patterns of clopidogrel metabolism during initiation and hence variable PRUs in the first month. After the PRUs reached the steady-state, a clear significant difference based on pharmacogenetic can be detected. The adequacy of PRUs may be assessed early during in-patient course but likely to differ significantly during the first days after initiation. Thus, if clopidogrel is on board, it may be judicious to assess the PRU just before the cardiac procedure and perhaps after one month of initiation to ensure a reasonable PRU for in-hospital stay and out-patient follow up.

No concrete PRU levels were well established. Besides, PRU have been proposed to range from 60-240 in several studies with heterogeneous cohorts. These studies contain multiple confounders, including: gender, age, diseases, medications, and procedures. For instance, while smokers showed more sensitivity toward PRU, females might show higher PRUs than males [15]. Therefore, It is suggested that a PRU cut-off value be assessed for each hospital based on their clinical data, as there is no clear consensus on the optimal PRUs.

Although the clinical benefits are very controversial, the possible clinical endpoints are devastating. It is clinically questionable to leave patients on clopidogrel with very minimal inhibitions when effective alternatives are available. All the proposed clinical decisions have been included in some of the guidelines under investigations or at most with very week level of evidence, including Up-to-Date [16,17]. At the same time, some guidelines have given the preference to Prasugrel or Ticagrelol in favour of clopidogrel in many clinical scenarios. Once a clinical endpoint occurred while on clopidogrel, most of the guidelines advocate screening for clopidogrel resistance and changing to other alternatives.

Finally, we suggest for clinicians to bear in mind clopidogrel resistance and to run PRU if feasible and easily accessible. If the patient shows very low PRU/inhibition rates lower than all the published data, it may be judicious to change to other alternatives. If alternatives are not available, close monitoring with patient education are warranted.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 7972
  • [From(publication date):
    February-2016 - Sep 20, 2017]
  • Breakdown by view type
  • HTML page views : 7897
  • PDF downloads :75

Review summary

  1. Jackie
    Posted on Aug 16 2016 at 1:59 pm
    The article reviews the pharmacogenetics and clinical impacts of clopidogrel on platelet function. The article is highly informative. The article not only updates on the recent research advancements in the field but also provides subjective knowledge of the pharmacological activities of clopidrogel.
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords